Related Experiment Video
Updated: Jan 31, 2026
Activation of Apoptosis by Cytoplasmic Microinjection of Cytochrome c
Published on: June 29, 2011
AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop
Danyang Chao1, Lijun Pang2, Ying Shi2
1Department of Laboratory, Zhecheng County People's Hospital of Henan Province, Shangqiu Henan, 476200, China.
Abstract:
AZD3759 is a tyrosine kinase inhibitor and has an encouraging future in treating brain metastases of non-small cell lung cancer. Here, we determined that AZD3759 suppressed the viability of HepG2 cells, a hepatoma cell line, and induced their apoptosis, suggesting a new therapeutic potential of AZD3759 in hepatocellular carcinoma (HCC) treatment. Furthermore, we found that the activation of p53-SMAD family member 4 (SMAD4) positive feedback loop was involved in the induction of bulks of apoptosis in HepG2 cells in response to AZD3759 treatment. In this positive feedback loop, p53 induced the expression of SMAD4 by directly promoting its transcription as shown by p53 could bind to SMAD4 promoter; SMAD4, in turn, promoted the nuclear translocation of p53, which increased the transcription of pro-apoptotic genes, including PUMA and BAX (two p53 target genes) and finally resulted in apoptosis. To the best of our knowledge, p53-induced SMAD4 transcription and SMAD4-determined the sub-location of p53 have not been reported. Taken together, our results demonstrated that AZD3759 might be an alternative strategy for HCC treatment and activating p53-SMAD4 positive feedback loop might enhance its therapeutic effects on HCC.
Insights
AZD3759, a tyrosine kinase inhibitor, shows promise for treating hepatocellular carcinoma (HCC) by inducing cancer cell death. Its mechanism involves activating a p53-SMAD4 feedback loop, enhancing apoptosis in HepG2 cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Targeted therapies are crucial for improving HCC treatment outcomes.
- AZD3759 is a tyrosine kinase inhibitor with potential anti-cancer properties.
Purpose of the Study:
- To investigate the therapeutic potential of AZD3759 in hepatocellular carcinoma (HCC).
- To elucidate the molecular mechanisms underlying AZD3759's effects on HCC cells.
- To explore the role of the p53-SMAD4 feedback loop in AZD3759-induced apoptosis.
Main Methods:
- Utilized HepG2 cells (a hepatoma cell line) to model HCC.
- Assessed the effects of AZD3759 on cell viability and apoptosis.
- Investigated the interaction between p53 and SMAD4 using molecular biology techniques, including promoter binding assays.
- Analyzed the transcriptional regulation of pro-apoptotic genes (PUMA, BAX).
Main Results:
- AZD3759 significantly suppressed HepG2 cell viability and induced apoptosis.
- The study identified a novel positive feedback loop between p53 and SMAD4.
- p53 directly induced SMAD4 transcription, and SMAD4 promoted p53 nuclear translocation.
- This feedback loop enhanced the transcription of pro-apoptotic genes, leading to increased apoptosis.
Conclusions:
- AZD3759 demonstrates potential as an alternative therapeutic strategy for HCC.
- Activation of the p53-SMAD4 positive feedback loop is a key mechanism for AZD3759's anti-cancer effects in HCC.
- Targeting this feedback loop may enhance the efficacy of AZD3759 in HCC treatment.
Related Concept Videos
01:18Positive and Negative Feedback Loops
01:01Feedback Loops
01:07Cell Signaling Feedback Loops
Negative feedback loops
Most signaling systems have negative feedback loops that can perform different functions such as output limiter, and adaptation.
Output limiter
Upon receiving an input signal, the cellular response rapidly increases until a threshold is reached. Beyond this threshold, a negative feedback loop...
01:23Root Loci for Positive-Feedback Systems
The construction rules for the root locus in positive feedback systems are similar to those in...
00:46Feedback Inhibition
01:30Apoptosis